David W. Henry

2.8k total citations · 1 hit paper
78 papers, 2.2k citations indexed

About

David W. Henry is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, David W. Henry has authored 78 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Organic Chemistry, 21 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in David W. Henry's work include Cancer Treatment and Pharmacology (9 papers), Synthesis and Characterization of Heterocyclic Compounds (8 papers) and Cancer therapeutics and mechanisms (8 papers). David W. Henry is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Synthesis and Characterization of Heterocyclic Compounds (8 papers) and Cancer therapeutics and mechanisms (8 papers). David W. Henry collaborates with scholars based in United States, Canada and Switzerland. David W. Henry's co-authors include Michael Cory, Joseph A. Miller, David D. McKee, Edward M. Acton, William W. Lee, Thomas H. Smith, Allan N. Fujiwara, George L. Tong, Helen Y. Wu and Paul Rogers and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

David W. Henry

74 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design, synthesis, and DNA binding properties of bifunctional intercalators. Comparison of polymethylene and diphenyl ether chains connecting phenanthridine

1985 416 citations Michael Cory, David D. McKee et al. Journal of the American Chemical Society profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David W. Henry United States	25	810	766	725	246	208	78	2.2k
Ti Li Loo United States	29	699 0.9×	301 0.4×	920 1.3×	140 0.6×	93 0.4×	103	2.4k
Daniel Glaubiger United States	28	1.0k 1.2×	254 0.3×	1.2k 1.7×	182 0.7×	171 0.8×	49	2.5k
Arlette Garnier‐Suillerot France	36	1.7k 2.1×	501 0.7×	1.6k 2.2×	325 1.3×	139 0.7×	119	3.2k
Krishna C. Agrawal United States	28	739 0.9×	495 0.6×	912 1.3×	82 0.3×	126 0.6×	101	2.6k
Renzo Canetta United States	30	2.2k 2.7×	344 0.4×	894 1.2×	150 0.6×	114 0.5×	61	3.9k
Marcel Rozencweig Belgium	30	1.9k 2.4×	366 0.5×	998 1.4×	206 0.8×	591 2.8×	151	4.0k
Maki Hasegawa Japan	27	622 0.8×	364 0.5×	701 1.0×	250 1.0×	55 0.3×	68	2.2k
Richard J. Jones United States	30	821 1.0×	306 0.4×	1.2k 1.6×	98 0.4×	606 2.9×	116	4.1k
Kenneth R. Harrap United Kingdom	33	2.3k 2.9×	963 1.3×	1.9k 2.6×	145 0.6×	62 0.3×	108	4.3k
Daniel S. Zaharko United States	27	552 0.7×	152 0.2×	1.0k 1.4×	198 0.8×	79 0.4×	64	2.7k

Countries citing papers authored by David W. Henry

Since Specialization

Citations

This map shows the geographic impact of David W. Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Henry more than expected).

Fields of papers citing papers by David W. Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Henry. The network helps show where David W. Henry may publish in the future.

Co-authorship network of co-authors of David W. Henry

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Henry. A scholar is included among the top collaborators of David W. Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Henry. David W. Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahmoudjafari, Zahra, et al.. (2020). Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. Journal of Oncology Pharmacy Practice. 26(7). 1566–1574. 3 indexed citations

Michaud, Laura Boehnke, et al.. (2019). Women in oncology pharmacy leadership: A white paper. Journal of Oncology Pharmacy Practice. 26(1). 175–186. 5 indexed citations

Henry, David W., et al.. (2016). Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Medical Oncology. 33(10). 107–107. 5 indexed citations

Skapek, Stephen X., James R. Anderson, David A. Hill, et al.. (2012). Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study. Pediatric Blood & Cancer. 60(7). 1108–1112. 90 indexed citations

Felgenhauer, Judy, Michael L. Nieder, Mark Krailo, et al.. (2012). A pilot study of low‐dose anti‐angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatric Blood & Cancer. 60(3). 409–414. 47 indexed citations

Grauer, Dennis, et al.. (2010). Effectiveness of Exogenous Albumin Administration for the Prevention of Ifosfamide‐Induced Encephalopathy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(8). 812–817. 16 indexed citations

Schwartzberg, Lee S., Patrick Cobb, Frank M. Senecal, et al.. (2009). Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. The Breast. 18(2). 78–83. 12 indexed citations

Cohen, Mark S., et al.. (2009). Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo. Annals of Surgical Oncology. 17(1). 296–303. 13 indexed citations

Rogers, Paul, Lillian R. Meacham, Kevin C. Oeffinger, David W. Henry, & Beverly J. Lange. (2005). Obesity in pediatric oncology. Pediatric Blood & Cancer. 45(7). 881–891. 87 indexed citations

10.

Henry, David W. & Aster Wardhani. (2003). Diagram recognition using hidden Markov models. QUT ePrints (Queensland University of Technology). 2 indexed citations

11.

Howard, Patricia, David W. Henry, & Jack E. Fincham. (1998). Assessment of Graduate Outcomes: Focus on Professional and Community Activities. American Journal of Pharmaceutical Education. 62(1). 31–36.

12.

Henry, David W.. (1997). Haematological toxicities associated with dose-intensive chemotherapy, the role for and use of recombinant growth factors. Annals of Oncology. 8. S7–S10. 12 indexed citations

13.

Chernak, Esther, Gary Dubin, David W. Henry, et al.. (1995). Infection Due to Parvovirus B19 in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 20(1). 170–173. 49 indexed citations

14.

Henderson, I. Craig, Joseph C. Allegra, Thomas Woodcock, et al.. (1989). Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.. Journal of Clinical Oncology. 7(5). 560–571. 198 indexed citations

15.

Cory, Michael, et al.. (1985). Design, synthesis, and DNA binding properties of bifunctional intercalators. Comparison of polymethylene and diphenyl ether chains connecting phenanthridine. Journal of the American Chemical Society. 107(8). 2528–2536. 416 indexed citations breakdown →

16.

Rideout, Janet L., David W. Henry, & L M Beacham. (1983). Nucleosides, nucleotides, and their biological applications : proceedings of the 5th international round table, October 20-22, 1982. Academic Press eBooks. 6 indexed citations

17.

Acton, Edward M., et al.. (1979). Improved antitumor effects in 3'-branched homologs of 2'-deoxythioguanine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose. Journal of Medicinal Chemistry. 22(5). 518–525. 60 indexed citations

18.

Lee, William W., Helen Y. Wu, Carol W. Mosher, et al.. (1975). Confirmation by synthesis of ristosamine as 3-amino-2,3,6-trideoxy-L-ribo-hexose. Journal of Medicinal Chemistry. 18(7). 767–768. 30 indexed citations

19.

Acton, Edward M., Allan N. Fujiwara, Leon Goodman, & David W. Henry. (1974). Synthetic C-nucleosides: 3-(α- and β-D-arabinofuranosyl)pyrazolo[4,3-d]pyrimidine-5,7-diones. Carbohydrate Research. 33(1). 135–151. 33 indexed citations

20.

Henry, David W.. (1969). Chemotherapeutic nitro-heterocycles. Derivatives of 5-nitrothiazole-2-carboxaldehyde and 5-nitrothiazole-2-carboxylic acid. Journal of Medicinal Chemistry. 12(2). 303–306. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact